By Therapeutic Area

Neurology & CNS (POTS, MSA, PAF, Autonomic Neuropathy) Market Analysis

Cross-industry research covering Neurology & CNS (POTS, MSA, PAF, Autonomic Neuropathy) across 1 market reportspanning Pharmaceuticals.

1 Reports

1 Industries

Reports Covering Neurology & CNS (POTS, MSA, PAF, Autonomic Neuropathy)

Dysautonomia Treatment Drugs Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR

Pharmaceuticals·Market: USD 4.8 Billion (2025)·CAGR: 7.2%

POTS and MSA together represent the highest-growth sub-segment, fueled by long-COVID diagnoses and orphan-drug pipeline activity including Lundbeck's MSA observational program (NCT05453058) and the Phase 1 sural nerve grafting study (NCT06683365). Academic publication density of 3,474 works since 2023 [openalex:topic-volume] underscores translational momentum.

38%

Market Share

8.1%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments